Free Trial

Roivant Sciences (ROIV) Stock Forecast & Price Target

$10.75
-0.26 (-2.36%)
(As of 07/24/2024 ET)

Roivant Sciences - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Based on 10 Wall Street analysts who have issued ratings for Roivant Sciences in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 10 analysts, 1 has given a hold rating, and 9 have given a buy rating for ROIV.

Consensus Price Target

$17.10
59.07% Upside
High Forecast$23.00
Average Forecast$17.10
Low Forecast$12.00

According to the 10 analysts' twelve-month price targets for Roivant Sciences, the average price target is $17.10. The highest price target for ROIV is $23.00, while the lowest price target for ROIV is $12.00. The average price target represents a forecasted upside of 59.07% from the current price of $10.75.

TypeCurrent Forecast
7/26/23 to 7/25/24
1 Month Ago
6/26/23 to 6/25/24
3 Months Ago
4/27/23 to 4/26/24
1 Year Ago
7/26/22 to 7/26/23
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Moderate Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
9 Buy rating(s)
9 Buy rating(s)
9 Buy rating(s)
7 Buy rating(s)
Hold
1 Hold rating(s)
1 Hold rating(s)
1 Hold rating(s)
1 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$17.10$16.90$16.90$14.71
Forecasted Upside59.07% Upside60.82% Upside60.11% Upside59.62% Upside
Get Roivant Sciences Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for ROIV and its competitors with MarketBeat's FREE daily newsletter.

ROIV Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

ROIV Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Roivant Sciences Stock vs. The Competition

TypeRoivant SciencesMedical CompaniesS&P 500
Consensus Rating Score
2.90
2.72
2.51
Consensus RatingModerate BuyModerate BuyModerate Buy
Predicted Upside59.07% Upside3,254.43% Upside10.61% Upside
News Sentiment RatingPositive News
Neutral News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
7/10/2024Piper Sandler
2 of 5 stars
 Boost TargetOverweight ➝ Overweight$20.00 ➝ $22.00+96.78%
6/18/2024Cantor Fitzgerald
3 of 5 stars
 Reiterated RatingOverweight
5/31/2024HC Wainwright
3 of 5 stars
 Reiterated RatingBuy ➝ Buy$18.00 ➝ $18.00+73.24%
4/3/2024The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$16.00 ➝ $18.00+65.44%
4/3/2024Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$14.00 ➝ $15.00+37.36%
3/25/2024Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy ➝ Buy$23.00+128.40%
2/15/2024Wolfe Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOutperform$17.00+50.18%
1/2/2024Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetNeutral ➝ Neutral$11.00 ➝ $12.00+5.91%
11/15/2023Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$17.00 ➝ $16.00+74.86%
11/14/2023JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOverweight ➝ Overweight$16.00 ➝ $15.00+61.12%
1/5/2023Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy$11.00 ➝ $14.00+85.19%
12/19/2022SVB Leerink
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform$8.00 ➝ $10.00+36.61%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 03:27 AM ET.

ROIV Forecast - Frequently Asked Questions

What is Roivant Sciences' forecast for 2024?

According to the research reports of 10 Wall Street equities research analysts, the average twelve-month stock price forecast for Roivant Sciences is $17.10, with a high forecast of $23.00 and a low forecast of $12.00.

Should I buy or sell Roivant Sciences stock right now?

10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Roivant Sciences in the last twelve months. There is currently 1 hold rating and 9 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" ROIV shares.

Does Roivant Sciences's stock price have much upside?

According to analysts, Roivant Sciences's stock has a predicted upside of 62.13% based on their 12-month stock forecasts.

What analysts cover Roivant Sciences?

Roivant Sciences has been rated by research analysts at Cantor Fitzgerald, HC Wainwright, and Piper Sandler in the past 90 days.

Do Wall Street analysts like Roivant Sciences more than its competitors?

Analysts like Roivant Sciences more than other "medical" companies. The consensus rating score for Roivant Sciences is 2.90 while the average consensus rating score for "medical" companies is 2.72. Learn more on how ROIV compares to other companies.


This page (NASDAQ:ROIV) was last updated on 7/25/2024 by MarketBeat.com Staff

From Our Partners